RNXT News & Events

RenovoRx announced that the FDA recently granted RenovoRx Orphan Drug Designation of oxaliplatin for the treatment of pancreatic cancer. The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act. Oxaliplatin is an approved and commonly used chemotherapy.

RenovoRx announced that an abstract from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting on May 29 - June 2, 2026. The abstract, entitled "The TIGeR-PaC Phase 3 Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study," is a sub-study of the Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer.

Reports Q1 revenue $563,000, consensus $463,250.